Zealand Pharma to host a Capital Markets Day in Copenhagen

Copenhagen, 2012-08-20 12:19 CEST (GLOBE NEWSWIRE) -- Investor News
No. 7/2012

-- Tuesday, 4 September 2012 from 12:00 – 16:30 CEST

-- The event will also be available via a live audio webcast with access to presentations via the company’s website

Copenhagen, Denmark – 20 August 2012 - Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, will host a Capital Markets Day for analysts and investors at the company’s headquarters in Glostrup, Copenhagen Denmark, on Tuesday, 4 September from 12:00 – 16:30 CEST.

The event will feature a presentation from Dr. Filip K. Knop, Head of Diabetes Research Division at Gentofte Hospital, University of Copenhagen. Dr. Knop is a leading diabetes expert and specialist in the field of GLP-1 based therapy, and he will discuss the relevance and potential for this drug class. 

Other guest speakers include Dr. Ruben Giorgino, Head of Drug Development at Helsinn Healthcare S.A, a pharmaceutical group with an important position in Cancer Supportive Care and one of Zealand Pharma’s license partners; and Dr. Barbara Ruskin, an IP and patent specialist and consultant to Zealand Pharma.

Presentations will also be given by Zealand Pharma’s management team, providing an update on the company’s product pipeline with particular focus on its lead invention, lixisenatide (Lyxumia®), a once-daily GLP-1 agonist licensed to Sanofi for the treatment of Type 2 diabetes. Management will also give an update on the status of the company’s partnership with Boehringer Ingelheim in diabetes/obesity.

The event can be followed via a live audio webcast including access to slide presentations, from the investor relations section of Zealand Pharma’s website (www.zealandpharma.com). Participants are advised to register for the webcast approximately 10 minutes before the start .A replay of the event will be available shortly after the event.  

# # #

For further information, please contact:

Hanne Leth Hillman, Vice President for IR & Corporate Communication,            

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide (Lyxumia®)¹, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. In November 2011, Sanofi filed for registration of lixisenatide in Europe and regulatory filing in the United States is expected in December 2012.

Zealand Pharma has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Abbott in acute kidney injury and Helsinn Healthcare in chemotherapy induced diarrhea. Zealand Pharma focuses its activities in disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com.

1. Lyxumia is the proprietary name submitted to the EMA for lixisenatide. The proprietary name for lixisenatide in the United States is under consideration. Lixisenatide is not currently approved or licensed anywhere in the world.